Real-world application of nirmatrelvir/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5 days: a comparative study.

Wen LuoKe-Yi LiChunmei DaiWenliang ZhuJuan LinFang LuQiujuan ChenWanyu WangQihong ZhuangYihua Lin

Published in: Infection (2024)

The application of Nirmatrelvir-ritonavir was associated with a significantly reduced risk of intubation or death in hospitalized COVID-19 patients who experienced symptoms for more than 5 days as compared to those who did not receive the treatment.

Keyphrases

coronavirus disease
sars cov
antiretroviral therapy
cardiac arrest
sleep quality
combination therapy
physical activity